VOGLIGOLD 0.2

Voglibose 0.2 mg is an oral anti-diabetic medicine belonging to the alpha-glucosidase inhibitor class. It works by slowing down the breakdown and absorption of carbohydrates in the small intestine, thereby controlling postprandial blood sugar levels (blood sugar after meals).VOGLIGOLD 0.2 by Steris Healthcare is designed for patients with Type 2 Diabetes Mellitus, helping to maintain steady blood glucose levels and prevent complications when combined with a healthy diet and regular exercise.

Uses of Voglibose 0.2 mg Tablets

The main voglibose 0.2 mg uses include:

• Treatment and management of Type 2 Diabetes Mellitus.

• Control of post-meal hyperglycemia.

• Often prescribed with other oral anti-diabetic drugs or insulin for better blood sugar control.

• Helps reduce the risk of long-term diabetes-related complications like neuropathy, kidney disease, and eye problems.

Side Effects of Voglibose 0.2 mg

Although voglibose tablets are generally well-tolerated, some patients may experience side effects such as:

• Abdominal discomfort or pain

• Flatulence (excess gas)

• Diarrhea

• Bloating

• Nausea

• Indigestion

• Loss of appetite

• Mild skin rashes or itching

• Constipation (rare)

• Fatigue or weakness

• Headache

• Dizziness

• Increased bowel sounds (borborygmi)

• Rarely, low blood sugar (hypoglycemia), especially when combined with sulfonylureas or insulin

Precautions Before Using Voglibose 0.2 mg Tablets

Before taking tab voglibose 0.2 mg, inform your doctor if you:

• Have severe kidney or liver problems.

• Suffer from inflammatory bowel disease or chronic intestinal disorders.

• Have a history of intestinal obstruction.

• Are pregnant, planning pregnancy, or breastfeeding.

• Are following a very low-carbohydrate diet (risk of hypoglycemia).

• Have had allergic reactions to voglibose or similar medicines in the past.

Drug Interactions – What Drugs Interact with Voglibose 0.2 mg?

Certain medicines may affect how voglibose 0.2 mg works or increase side effects. These include:

• Sulfonylureas (e.g., glimepiride, glibenclamide) – may cause hypoglycemia.

• Insulin – increases the risk of low blood sugar.

• Digestive enzymes (e.g., amylase, pancreatin) – may reduce voglibose’s effectiveness.

• Activated charcoal – may decrease absorption of voglibose.

• Other alpha-glucosidase inhibitors – may increase gastrointestinal side effects.